Advertisement
"Ev has done an impressive job as acting CEO in managing the transition ofour company and building a platform for the future," said Peter Davis,Chairman of the TorreyPines Board of Directors. "We are delighted that shehas agreed to become CEO and a member of the Board at a time when TorreyPinesis completing important clinical trials that hold promise for the company'sfuture. With her considerable drug development experience as well as globalsenior management roles, she has the right mix of skills and experience tosuccessfully lead the Company in meeting its strategic objectives."
Advertisement
"I am excited by this opportunity and look forward to continuing to workwith TorreyPines' talented management team and dedicated employees," said Ms.Graham.
Ms. Graham joined TorreyPines in 2004 as Vice President, Development. Shewas then promoted to Vice President, Corporate Development in 2005, ChiefOperating Officer in 2006 and acting Chief Executive Officer in September2008. Prior to joining TorreyPines Ms. Graham was Executive Director,Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000,she was Senior Vice President of Business Development at IngenixPharmaceutical Services, a division of UHG, and served as Vice President ofClinical Operations at Worldwide Clinical Trials, prior to its acquisition byUHG. Previously, Ms. Graham held positions in operations management,healthcare utilization and organizational planning at Bayer Corporation andWyeth Pharmaceuticals (formerly Ayerst Laboratories). Ms. Graham holds a B.A.in biology from the University of Delaware and an M.B.A. from the Universityof Connecticut.
About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed toproviding patients with better alternatives to existing therapies through theresearch, development and commercialization of small molecule compounds. Thecompany's goal is to develop versatile product candidates each capable oftreating a number of acute and chronic diseases and disorders such asmigraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders.The company is currently developing three product candidates: two ionotropicglutamate receptor antagonists and one muscarinic receptor agonist. Furtherinformation is available at http://www.torreypinestherapeutics.com.
This press release contains forward-looking statements or predictions.Such statements are subject to numerous known and unknown risks, uncertaintiesand other factors, which may cause TorreyPines' actual results to bematerially different from historical results or from any results expressed orimplied by such forward-looking statements. These and other risks which maycause results to differ are described in greater detail in the "Risk Factors"section of TorreyPines' annual report on Form 10-K for the year ended December31, 2007 and TorreyPines other SEC reports. The forward-looking statements arebased on current information that is likely to change and speak only as of thedate hereof.Company contact: Investor contact: Paul Schneider Rhonda Chiger TorreyPines Therapeutics, Inc. Rx Communications Group 858-623-5665 X125 (917) 322-2569 [email protected] [email protected]
SOURCE TorreyPines Therapeutics, Inc.
